LRRC15, short for leucine-rich repeat containing 15, is a transmembrane protein that sits on the surface of certain cells and helps mediate interactions between cells and the surrounding tissue scaffold. It belongs to a large family of proteins that share a common structural motif, but LRRC15 stands out because of where it shows up and what it does when it gets there. In healthy tissue, it is barely detectable in most organs. In disease, it surges in the stromal cells surrounding tumors, in inflamed joints, in fibrotic lungs, and even in lung tissue fighting SARS-CoV-2 infection. That combination of near-silence in healthy tissue and loud activation in disease has made it one of the more closely watched targets in cancer drug development and a growing area of interest in fibrosis, arthritis, and viral immunology.
A Protein That Is Mostly Absent From Normal Tissue
One of the defining features of LRRC15 is how little of it exists in a healthy body. Broad screening of human tissues found that LRRC15 messenger RNA and protein are generally absent from most organs.1Cancer Research. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates The exceptions are oddly specific: hair follicles, tonsils, the cardia and pylorus regions of the stomach, a narrow zone of the spleen, osteoblasts (the cells that build bone), and sites where wounds are actively healing. That restricted expression is a big deal for drug developers. When a protein is plastered across every organ, targeting it with a drug risks damaging healthy tissue. When it is confined to a handful of specialized spots in normal tissue but dramatically upregulated in disease, you have a much cleaner therapeutic window.
The Cancer-Associated Fibroblast Connection
The place LRRC15 attracted the most attention earliest was in the tumor microenvironment. Solid tumors are not just masses of cancer cells. They are surrounded and infiltrated by a supporting cast of non-cancerous cells, blood vessels, and connective tissue proteins collectively called the stroma. Among the most important stromal players are cancer-associated fibroblasts, or CAFs. These are fibroblasts that have been co-opted by the tumor into producing growth factors, remodeling the tissue scaffold, and helping the tumor evade immune attack. LRRC15 is selectively expressed on these CAFs and has become a promising biomarker for imaging and targeting the tumor microenvironment.2PubMed Central. Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblasts
In tumors that are described as desmoplastic, meaning they have a dense, fibrous stroma, LRRC15 tends to be especially enriched. Pancreatic cancer, breast cancer, and head-and-neck cancers fall into this category. The protein’s presence in these tumors has been associated with therapy resistance and immune evasion.3PubMed. LRRC15 in tumorigenesis, progression, and therapy That is not just a side observation. A protein that helps tumors resist treatment and dodge immune cells is a protein worth understanding and, ideally, neutralizing.
Which Tumors Have It and Which Do Not
Not every cancer expresses LRRC15. A large survey of tumor tissue found that stromal LRRC15 was widespread in breast cancer (about 94% of samples across all subtypes), head-and-neck cancers (81%), non-small-cell lung cancer (roughly two thirds of both adenocarcinoma and squamous subtypes), and pancreatic cancer (66%). The protein was also detected in the stroma of metastatic sites including lymph nodes, bone, and liver. Certain cancers with mesenchymal characteristics, such as sarcomas, glioblastoma, and melanoma, showed LRRC15 expression on both cancer cells and stroma.1Cancer Research. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
On the other side of the ledger, some cancers had almost none. Renal cancer samples were positive in only about 3% of cases, prostate cancer in 0%, and gastrointestinal stromal tumors (GISTs) also in 0%. That variation matters clinically. A drug targeting LRRC15 would likely be useful in pancreatic or breast cancer but would have little reason to exist for prostate cancer.
How LRRC15 Drives Invasion in Triple-Negative Breast Cancer
Beyond its role in the supporting stroma, LRRC15 can directly influence the behavior of cancer cells themselves. In triple-negative breast cancer, which is among the hardest subtypes to treat, experiments showed that knocking down LRRC15 reduced the ability of cancer cells to migrate and invade through tissue barriers. Overexpressing it had the opposite effect, boosting their invasive capacity.4Scientific Reports. Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway The protein appears to work through an integrin signaling pathway that connects the cell surface to internal growth and movement signals. In practical terms, LRRC15 is not just a passive bystander in the tumor microenvironment. It actively helps cancer cells become more aggressive.
An Unexpected Role in SARS-CoV-2 Defense
The COVID-19 pandemic brought LRRC15 into a completely different spotlight. Multiple research groups independently discovered that LRRC15 binds the spike protein of SARS-CoV-2, the same protein that the virus uses to latch onto its main entry receptor, ACE2. But here is the twist: LRRC15 does not let the virus in. Cells expressing only LRRC15 can grab the spike protein but cannot be infected.5PLoS Biology. Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs
More interesting still, LRRC15 appears to act as a decoy that mops up virus and prevents it from reaching vulnerable cells nearby. When LRRC15-expressing fibroblasts were placed alongside ACE2-positive cells (the cells the virus normally infects), infection rates dropped. The protein inhibited spike-mediated viral entry “in trans,” meaning it protected neighboring cells without needing to be on those cells itself.6PubMed Central. LRRC15 inhibits SARS-CoV-2 cellular entry in trans A separate study confirmed that LRRC15 binds the same receptor-binding domain of the spike that ACE2 recognizes, though through a distinct mechanism unrelated to heparan sulfates or lectin receptors.7PubMed Central. LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein
LRRC15 levels were greatly elevated in the lungs of COVID-19 patients, driven by inflammatory signals. The picture that emerges is that LRRC15 is part of an innate immune barrier: fibroblasts in the lung vasculature ramp up LRRC15 during infection, essentially deploying sticky decoys that sequester virus and slow its spread. It cannot save cells that are already infected, but it can reduce the number of cells that get infected in the first place.
TGF-β and the Switch to a Profibrotic State
To understand why LRRC15 pops up in such seemingly unrelated conditions, from cancer to COVID to arthritis, you need to understand what turns it on. The primary upstream signal is TGF-β, a growth factor that plays a central role in wound healing, tissue remodeling, and fibrosis. Research has identified TGF-β signaling as the key regulator that flips fibroblasts from a proliferative, wound-healing state into a profibrotic myofibroblast state, and LRRC15 is highly restricted to that myofibroblast population.8PubMed Central. TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15 In other words, LRRC15 marks a specific flavor of activated fibroblast, one whose primary program is remodeling the extracellular matrix.
This same TGF-β-driven process operates in multiple tissues. In periodontal ligament fibroblasts, low concentrations of TGF-β1 triggered differentiation and a significant increase in LRRC15, which accumulated on the cell surface in a glycosylated form and supported cell adhesion through integrin signaling.9Stem Cells. Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-β1-Induced PDL Fibroblastic Differentiation Inflammatory cytokines like IL-1β can also induce LRRC15, which helps explain its appearance in inflamed tissue even when TGF-β is not the dominant signal.10PubMed Central. The Molecular Structure, Expression, and Emerging Role of the 15-Leucine-Rich Repeat Containing Membrane Protein (LRRC15) in Skeletal Biology and Diseases
LRRC15 in Fibrosis and Scarring
Given its tight association with TGF-β-driven myofibroblasts, it is no surprise that LRRC15 keeps appearing in fibrotic diseases. In idiopathic pulmonary fibrosis, bleomycin treatment (a standard experimental trigger for lung fibrosis) caused LRRC15 levels to rise sharply in both mouse lung tissue and human lung epithelial cells. When researchers silenced LRRC15 in those cells, some of the bleomycin-induced damage was partially reversed, and autophagy, the cell’s internal recycling system, was enhanced.11PubMed. Effect of LRRC15 on autophagy in A549 cells The findings suggest that LRRC15 may actively participate in the fibrotic process rather than just sitting on the surface of fibrotic cells as a bystander marker.
State-level analysis has linked LRRC15-positive myofibroblasts to extracellular matrix remodeling programs in pulmonary fibrosis and to disease-specific fibroblast programs in human skin, including in hidradenitis suppurativa, a chronic inflammatory condition associated with scarring.12PubMed Central. LRRC15+ Myofibroblasts as a Stromal State Linking Repair, Fibrosis, and Scarring The evidence here is still developing, though. While there is strong data that LRRC15 marks a profibrotic cell state across tissues, direct causal evidence that LRRC15 itself drives scarring (as opposed to simply traveling with the cells that do) remains limited.
Joint and Bone Disease
LRRC15 has drawn attention in skeletal biology as well. In osteoarthritis, researchers found increased LRRC15 protein in damaged cartilage and in areas where osteophytes (bony spurs) were forming. The protein was also prominent in postnatal growth plates, the zones where bone lengthens during development.13PubMed Central. Transcriptomic and epigenomic analyses uncovered Lrrc15 as a contributing factor to cartilage damage in osteoarthritis When LRRC15 was knocked down in chondrocytes (cartilage cells), the IL-1β-driven expression of several destructive enzymes relevant to osteoarthritis, including MMP13 and MMP3, was reduced.14Osteoarthritis and Cartilage. Epigenetic and transcriptomic changes in early and established post-traumatic osteoarthritis
The picture that emerges is that LRRC15 may be an early event in the chondrocyte activation that characterizes osteoarthritis, contributing to the cascading tissue damage by coordinating stress responses and dysregulated matrix remodeling. LRRC15 has also been detected in osteoclasts from patients with rheumatoid arthritis and has been connected to the processes underlying osteoporosis, though the evidence on those fronts is less developed.10PubMed Central. The Molecular Structure, Expression, and Emerging Role of the 15-Leucine-Rich Repeat Containing Membrane Protein (LRRC15) in Skeletal Biology and Diseases The protein’s emerging role in osteosarcoma, the most common primary bone cancer, has further reinforced the idea that LRRC15 is a significant player in skeletal biology across both healthy development and disease.
Drug Development Targeting LRRC15
The therapeutic interest in LRRC15 centers on antibody-drug conjugates, a class of drugs that stitch together an antibody (which finds and binds a target on cell surfaces) and a toxic payload (which kills cells once delivered). The logic for targeting LRRC15 with an ADC is appealing: the protein is rare in normal tissue, abundant in the tumor stroma, and present on the surface of cells, making it accessible to circulating antibodies.
The most advanced LRRC15-targeting ADC is ABBV-085, which carries a toxin called MMAE. In preclinical testing, ABBV-085 showed robust activity against both tumors where the cancer cells themselves express LRRC15 and tumors where only the surrounding stroma is positive. Its mechanism relied on MMAE’s ability to cross cell membranes after being released, allowing it to preferentially kill nearby cancer cells even when the drug initially docked on a stromal fibroblast rather than a cancer cell. This “bystander effect” also appeared to increase immune cell infiltration into the tumor.1Cancer Research. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
In a first-in-human phase I trial, patients with osteosarcoma or undifferentiated pleomorphic sarcoma treated at the highest dose had an overall response rate of about 20%, with several patients achieving meaningful tumor shrinkage.15Clinical Cancer Research. First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors For osteosarcoma, a cancer notoriously resistant to new drugs, even modest response rates in early trials are considered encouraging. In preclinical osteosarcoma models using a more potent toxin payload, cure rates ranged from 40% to 100%, and even cell lines with low LRRC15 could be sensitized to the drug by pre-treating them with TGF-β to re-induce LRRC15 expression.16PubMed Central. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies
The First High-Resolution Structure
For years, researchers knew what LRRC15 did but not exactly what it looked like at the atomic level. That changed with a cryo-electron microscopy study that resolved the structure of LRRC15 bound to samrotamab, a therapeutic antibody, at 2.6 angstrom resolution. The study revealed that LRRC15 has an open arc geometry, with samrotamab binding to a membrane-proximal epitope in the protein’s C-terminal region. That binding site leaves the concave surface of the arc, the canonical interaction surface for leucine-rich repeat proteins, completely exposed.17bioRxiv. Cryo-EM structure of human LRRC15 reveals the basis of therapeutic antibody recognition This means the antibody can latch on without blocking whatever signaling LRRC15 normally does through that concave face. For drug designers, having the three-dimensional structure in hand opens the door to engineering new molecules that can target different surfaces of LRRC15, potentially blocking its pro-tumor or profibrotic functions more directly.
Why One Protein Keeps Showing Up Everywhere
It can seem strange that the same molecule keeps appearing in cancer stroma, arthritic joints, fibrotic lungs, and antiviral defense. The common thread is the activated fibroblast. Fibroblasts are the body’s tissue architects. Under normal conditions they maintain connective tissue quietly. When tissue is damaged by injury, infection, or a growing tumor, fibroblasts get activated, often through TGF-β or inflammatory cytokines, and begin remodeling the extracellular matrix. LRRC15 marks a particular flavor of this activation, the matrix-remodeling myofibroblast state. Whether the trigger is a tumor secreting TGF-β to build its own protective stroma, a virus prompting lung fibroblasts to mount an immune response, or inflamed cartilage sending distress signals, the downstream machinery overlaps. LRRC15 is not causing all of these conditions independently. It is a surface marker and functional participant in a fibroblast program that gets reused across diseases.
That shared biology is also what makes it such a useful target. A biomarker that appears in the stroma of multiple hard-to-treat cancers, that is nearly absent from normal tissue, and that participates in therapy resistance is exactly the kind of molecule the pharmaceutical industry wants to build drugs against. The lingering question is how much of LRRC15’s appeal is as a convenient address label for drug delivery versus how much it is a functional driver that, if blocked, would independently slow disease. The evidence is growing that it plays an active role, particularly through integrin and NF-κB signaling pathways, but separating a protein’s marker function from its causal function is one of the harder problems in biology and remains an active area of investigation.